XML 41 R30.htm IDEA: XBRL DOCUMENT v3.22.2.2
Stockholders' Equity (Tables)
9 Months Ended
Sep. 30, 2022
Schedule of allocation of total stock-based compensation expense

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

(In thousands)

    

2022

    

2021

    

2022

    

2021

Cost of revenue

$

67

$

171

$

281

$

455

Sales and marketing expenses

1,101

1,081

3,352

2,979

Research and development expenses

54

68

175

224

Reimbursement, general and administrative expenses

1,338

1,268

3,873

4,045

Total stock-based compensation expense

$

2,560

$

2,588

$

7,681

$

7,703

Schedule of stock option activity

    

Weighted-

Weighted-

Average

Average

Aggregate

Options

Exercise Price

Remaining

Intrinsic

(In thousands except options and per share data)

Outstanding

Per Share (1)

Contractual Life

Value (2)

Balance at December 31, 2021

915,224

$

39.33

5.0 years

$

2,068

Granted

$

Exercised

(90,878)

$

1.68

$

916

Forfeited

(58,115)

$

46.93

Cancelled/Expired

(152,448)

$

36.62

Balance at September 30, 2022

613,783

$

44.86

4.8 years

$

44

Options exercisable at September 30, 2022

402,979

$

44.18

4.7 years

$

44

(1)The exercise price of each option granted during the period shown was equal to the market price of the underlying stock on the date of grant.
(2)The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.
Time-Based Restricted Stock Units  
Schedule of stock-settled restricted stock unit activity

Weighted-

    

    

Average Grant

    

Aggregate

Units

Date Fair Value

Intrinsic

(In thousands except unit and per unit data)

Outstanding

Per Unit

Value (1)

Balance at December 31, 2021

259,147

$

42.32

$

4,932

Granted

496,302

$

15.64

Vested

(93,444)

$

46.84

Cancelled

(54,299)

$

29.98

Balance at September 30, 2022

607,706

$

20.94

$

4,734

(1)The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of the period.
Performance-based stock-settled restricted stock units  
Schedule of stock-settled restricted stock unit activity

Performance-

Weighted-

    

Based

    

Average Grant

    

Aggregate

Units

Date Fair Value

Intrinsic

(In thousands except unit and per unit data)

Outstanding

Per Unit

Value (1)

Balance at December 31, 2021

54,317

$

50.22

$

1,034

Granted

131,710

$

18.54

Vested

(1,853)

$

19.03

Cancelled

(20,147)

$

23.18

Balance at September 30, 2022

164,027

$

25.11

$

1,278

(1)The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.